Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.05 | N/A | -600.00% |
management commentary, guidance changes, and full analysis available with Pro.
| -600.00% |
Tone: Defensive
Management expressed concerns about the ongoing market conditions affecting performance. They did not offer any forward guidance, indicating uncertainty.
Management did not provide specific guidance for future performance.
The company acknowledged challenges in the current market environment.
Ligand Pharmaceuticals reported a loss per share that was worse than expected, which contributed to a decline in its stock price by 3.69%. The lack of revenue figures and guidance adds to investor uncertainty. Overall, the company appears to be facing challenges that may impact its future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PPL CORP
Aug 5, 2011